Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient.
Pablo Salmón OlavarríaSaioa Rubio IturriaÓscar Nantes-CastillejoPublished in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)
Pyoderma gangrenosum (PG) is a difficult-to-manage ulcero-necrotizing dermatosis associated with inflammatory bowel disease (IBD). In this article, we report a refractory PG in a patient with severe ulcerative colitis (UC) that responded to tofacitinib 10 mg/12 h.